Consensus on the utility of bone markers in the malignant bone disease setting

Robert E. Coleman; Luís Costa; Fred Saad; Richard J. Cook; Peyman Hadji; Evangelos Terpos; Patrick Garnero; Janet E. Brown; Jean‐Jacques Body; Matthew Smith; Ker‐Ai Lee; Pierre Major; Meletios A Dimopoulos; Allan Lipton

doi:10.1016/j.critrevonc.2011.02.005

Related publications

Letter2016

Radionuclide therapy of malignant bone lesions

Manfred M. Fischer, H. J. Biersack

European Journal of Nuclear Medicine and Molecular Imaging

Letter2007

Polytetrafluoroethylene‐covered stent deployment in the setting of Kawasaki disease

Hae Sik Kwon, Jae Il Shin, Jae Young Choi, Jun Hui Sul, Yangsoo Jang

Letter2022

Utility of next generation sequencing for differentiating malignant PEComa from metastatic melanoma

Elizabeth C. Paver, Karina Aivazian, Fiona Maclean, Georgina V. Long, Andrew J. Spillane, James S. Wilmott, Richard A Scolyer

Article2017

Bone turnover markers in sheep and goat: A review of the scientific literature

José Arthur de Abreu Camassa, Camila Cardoso Diogo, Cristina P. Sousa, Jorge Manuel Teixeira de Azevedo, Carlos Viegas, Rui L Reis, Nuno Dourado, Isabel R. Dias

Article2014

Mo1369 Utility of EUS-Guided Gallbladder Drainage for Rescue Treatment of Malignant Biliary Obstruction

Hajime Imai, Masayuki Kitano, Masatoshi Kudo, Hiroki Sakamoto, Ken Kamata, Takeshi Miyata, Kumpei Kadosaka, Shunsuke Omoto, Kentaro Yamao